Announcements & Media Coverage

HEMO-CAR-T Update - 7:05 3/03/2021
Hemogenyx Pharmaceuticals plc (“Hemogenyx Pharmaceuticals” or the “Company”)   HEMO-CAR-T Update   Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to issue an update on the development of its leading product candidate Chimeric Antigen Receptor (“CAR”) T-cells (“HEMO-CAR-T”). As announced on 5 January, 2021 the...